Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

• Revenue in USD (TTM)80.33m
• Net income in USD29.34m
• Incorporated2013
• Employees97.00

• Location
  Theravance Biopharma IncUGLAND HOUSE, SOUTH CHURCH STREETGEORGE TOWN KY1-1104Cayman IslandsCYM
• Phone+1 3456 508086000
• Websitehttps://www.theravance.com/